CXCL13 expressed on inflamed cerebral blood vessels recruit IL-21 producing T FH cells to damage neurons following stroke

• Published in: Journal of neuroinflammation 2022-05, Vol.19 (1), p.125
• Main Authors: Rayasam, Aditya, Kijak, Julie A, Kissel, Lee, Choi, Yun Hwa, Kim, Taehee, Hsu, Martin, Joshi, Dinesh, Laaker, Collin J, Cismaru, Peter, Lindstedt, Anders, Kovacs, Krisztian, Vemuganti, Raghu, Chiu, Shing Yan, Priyathilaka, Thanthrige Thiunuwan, Sandor, Matyas, Fabry, Zsuzsanna
• Format: Article
• Language: English
• Subjects: Animals; Brain Injuries - metabolism; Brain Ischemia - metabolism; Chemokine CXCL13 - metabolism; Humans; Infarction, Middle Cerebral Artery - pathology; Inflammation Mediators - metabolism; Interleukins; Ischemia - pathology; Janus Kinases - metabolism; Mice; Neurons - metabolism; Signal Transduction; STAT Transcription Factors - metabolism; Stroke - pathology
• ISSN: 1742-2094

Ischemic stroke is a leading cause of mortality worldwide, largely due to the inflammatory response to brain ischemia during post-stroke reperfusion. Despite ongoing intensive research, there have not been any clinically approved drugs targeting the inflammatory component to stroke. Preclinical studies have identified T cells as pro-inflammatory mediators of ischemic brain damage, yet mechanisms that regulate the infiltration and phenotype of these cells are lacking. Further understanding of how T cells migrate to the ischemic brain and facilitate neuronal death during brain ischemia can reveal novel targets for post-stroke intervention. To identify the population of T cells that produce IL-21 and contribute to stroke, we performed transient middle cerebral artery occlusion (tMCAO) in mice and performed flow cytometry on brain tissue. We also utilized immunohistochemistry in both mouse and human brain sections to identify cell types and inflammatory mediators related to stroke-induced IL-21 signaling. To mechanistically demonstrate our findings, we employed pharmacological inhibitor anti-CXCL13 and performed histological analyses to evaluate its effects on brain infarct damage. Finally, to evaluate cellular mechanisms of stroke, we exposed mouse primary neurons to oxygen glucose deprivation (OGD) conditions with or without IL-21 and measured cell viability, caspase activity and JAK/STAT signaling. Flow cytometry on brains from mice following tMCAO identified a novel population of cells IL-21 producing CXCR5+ CD4+ ICOS-1+ T follicular helper cells (T ) in the ischemic brain early after injury. We observed augmented expression of CXCL13 on inflamed brain vascular cells and demonstrated that inhibition of CXCL13 protects mice from tMCAO by restricting the migration and influence of IL-21 producing T cells in the ischemic brain. We also illustrate that neurons express IL-21R in the peri-infarct regions of both mice and human stroke tissue in vivo. Lastly, we found that IL-21 acts on mouse primary ischemic neurons to activate the JAK/STAT pathway and induce caspase 3/7-mediated apoptosis in vitro. These findings identify a novel mechanism for how pro-inflammatory T cells are recruited to the ischemic brain to propagate stroke damage and provide a potential new therapeutic target for stroke.